Local
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: BioSpace

Less than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic. PharmaLogic has struck a deal to buy a radiopharmaceutical contract development and manufacturing organization (CDMO) and production plant from Lantheus. Lantheus acquired the CDMO and Springfield, New Jersey, production facility last year when it bought Evergreen Theragnostics for $250 million upfront. At the time, Lantheus hailed Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO as a boost for its business. Yet, 19 months after closing the deal, Lantheus has agreed to offload the CDMO and New Jersey plant. PharmaLogic is buying the assets for an undisclosed sum to advance toward its goal of creating the first fully integrated, global CDMO specializing in radiopharmaceutical therapies.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at BioSpace



